Related Experiment Video

Updated: Feb 26, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.7K

[Inhibitors of PCSK9]

Iveta Petrova-Slater1, Andrea Denegri2, Elena Pasotti2

  • 1Cardiocentro Ticino, Servizio ricerca cardiovascolare, Via Tesserete 48, 6900 Lugano.

Revue Medicale Suisse
|July 21, 2017
PubMed

Insights

New PCSK9 inhibitor drugs offer a promising approach to further reduce cardiovascular disease (CVD) risk in patients with high low-density lipoprotein cholesterol (LDL-C) who do not benefit enough from statins.

Area of Science:

  • Cardiovascular medicine
  • Lipidology
  • Pharmacology

Background:

  • Elevated low-density lipoprotein cholesterol (LDL-C) is strongly associated with cardiovascular disease (CVD).
  • Statins effectively lower LDL-C but may cause side effects and leave residual CVD risk.
  • Significant residual risk persists in patients undergoing statin therapy for CVD prevention.

Purpose of the Study:

  • To review the mechanism of action of proprotein convertase subtilisin kexin 9 (PCSK9) antibodies.
  • To discuss the safety and efficacy of PCSK9 antibodies in phase III clinical trials.
  • To highlight PCSK9 inhibitors as a novel hypolipidemic treatment option.

Main Methods:

  • Review of existing observational data and clinical trial results.
  • Analysis of the pharmacological action of PCSK9 inhibition.
  • Synthesis of safety and efficacy data from phase III studies of PCSK9 antibodies.

Main Results:

  • PCSK9 antibodies demonstrate a potent LDL-C lowering effect.
  • Phase III studies indicate favorable safety and efficacy profiles for PCSK9 inhibitors.
  • These agents represent a significant advancement in managing hyperlipidemia and reducing CVD risk.

Conclusions:

  • PCSK9 antibodies provide a novel therapeutic strategy for managing hyperlipidemia.
  • They offer an effective option for patients with statin-intolerant or statin-resistant hypercholesterolemia.
  • This class of drugs holds significant promise for further reducing residual CVD risk.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

11.3K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
780
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
593
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
93.3K